药物涂层球囊治疗股腘动脉病变的日常实践中期结果
本研究回顾性纳入2015年1月至2016年9月所有接受药物涂层球囊(DCB)治疗的股腘动脉病变患者,无排除标准,评估中期通畅率及再狭窄危险因素。共109例患者(113条腿),平均随访24±13个月,1、2、3年一期通畅率分别为87%、79%、61%,仅TASC D病变与再狭窄独立相关(P=0.008)。
要点
- 日常实践中DCB治疗股腘动脉病变1、2年通畅率优良,3年略降。
- 仅TASC D病变是再狭窄的独立危险因素(P=0.008)。
- 3年主要靶肢体截肢率5%,总死亡率18%。
核心结论
- DCB血管成形术在日常实践中治疗股腘动脉病变有效且安全,1年和2年结果优异,3年结果略差。
研究设计与样本
- 回顾性队列研究,纳入2015年1月至2016年9月所有接受DCB治疗的股腘动脉病变患者,无排除标准,共109例患者(113条腿),平均年龄72±10岁,男性45%。
主要发现
- 1、2、3年一期通畅率分别为87%、79%、61%。
- 1、2、3年一期辅助通畅率分别为95%、89%、79%;二期通畅率分别为99%、97%、91%。
- 1、2、3年临床驱动靶病变血运重建率分别为6.9%、14.3%、20.6%。
- 3年总死亡率和主要靶肢体截肢率分别为18%和5%。
- 多变量分析显示仅TASC D病变与再狭窄相关(P=0.008)。
关键数值与推荐
- 临界肢体缺血比例52%,总闭塞病变治疗比例38%。
临床怎么用
- 日常实践中可考虑将DCB作为股腘动脉病变的治疗选择,但TASC D病变患者需警惕再狭窄风险。
局限性
- 回顾性研究,样本量有限(109例),随访时间平均24±13个月,可能受限于单中心数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most previous drug-coated balloon (DCB) angioplasty studies used strict inclusion and exclusion criteria and therefore might not be representative for daily practice. This study was performed to evaluate the midterm outcomes of DCB angioplasty in femoropopliteal artery disease and to identify risk factors for restenosis. MATERIALS AND METHODS: All patients treated with DCB angioplasty between January 2015 and September 2016 were included. Provisional stents were placed if indicated. Data were retrospectively collected from digital patient records. No exclusion criteria were applied. The primary end point was primary patency. Secondary end points were primary assisted patency, secondary patency, clinically driven target lesion revascularization (CD-TLR) and major adverse events. All end points were calculated with the Kaplan-Meier analysis. The univariable and multivariable Cox regression analyses were performed to identify risk factors for restenosis. RESULTS: A total of 109 patients (113 legs) were included (45% male; mean age, 72 ± 10). The rate of critical limb ischemia was 52% and total occlusions were treated in 38%. The mean follow-up was 24 ± 13 months. Primary patency rates were 87%, 79%, and 61% at 1, 2, and 3 years, respectively. Primary assisted patency rates were 95%; 89%, and 79%; secondary patency rates were 99%, 97%, and 91%; and CD-TLR rates were 6.9%, 14.3%, and 20.6% at 1, 2, and 3 years, respectively. Overall mortality and major target limb amputation rates were 18% and 5% at 3 years. Multivariable analysis demonstrated that only Trans-Atlantic Inter-Society Consensus (TASC) D lesions were associated with restenosis (P = 0.008). CONCLUSIONS: DCB angioplasty is an effective and safe treatment option for femoropopliteal lesions in daily practice with excellent 1- and 2-year results. The 3-year results were slightly less favorable, which may be caused by the ongoing vascular disease or a late "catch-up" phenomenon. Only TASC D lesions were associated with loss of primary patency after adjustment for confounders.
引用
- Nugteren M, Serné A, Verhoeven B, et al. Midterm Outcomes of Drug-Coated Balloon Angioplasty in Femoropopliteal Lesions in a Daily Practice Cohort. Ann Vasc Surg. 2019. PMID: 31634609. doi:10.1016/j.avsg.2019.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。